Wockhardt Limited (NSE: WOCKPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 200.39B |
| Revenue (ttm) | 29.81B |
| Net Income (ttm) | -2.88B |
| Shares Out | 162.47M |
| EPS (ttm) | -19.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 573,490 |
| Open | 1,180.00 |
| Previous Close | 1,174.70 |
| Day's Range | 1,169.60 - 1,233.40 |
| 52-Week Range | 323.50 - 1,334.65 |
| Beta | 1.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 13, 2025 |
About Wockhardt
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram nega... [Read more]
Financial Performance
In 2023, Wockhardt's revenue was 28.30 billion, an increase of 6.51% compared to the previous year's 26.57 billion. Losses were -4.63 billion, -17.17% less than in 2022.
Financial StatementsNews
Wockhardt shares jump 4% on Q2 FY25 results
Wockhardt’s stock saw a 4% increase after the company reported promising Q2 FY25 results. Revenue from operations grew by 7.4% year-over-year to ₹809 crore, up from ₹753 crore in Q2 FY24. Sequentially...
Workhardt Q2 FY25 Results: Revenue up 7.43% YoY to Rs 809 crore, Net Loss widens to Rs 22 crore
Wockhardt Limited announced its Q2 FY25 financial results, reflecting moderate revenue growth alongside persistent losses. Here are the key highlights of Wockhardt’s performance for the quarter: Reven...
Wockhardt Q2 FY25 results: Stock drops 3% ahead of result announcement
Wockhardt’s stock saw a decline of over 3% as investors await its Q2 FY25 results. The shares opened at ₹1,198, reaching a high of ₹1,198 before slipping to a low of ₹1,140.10 during trading. Despite ...
Wockhardt files Insulin Aspart injection with DCGI, reinforcing diabetes management commitment
Wockhardt, a global pharmaceutical and biotechnology company, has filed its fast-acting insulin analog, Aspart injection (ASPARAPIDTM), with the Drugs Controller General of India (DCGI). This developm...
Wockhardt’s WCK 6777 earns Fast Track Designation from USFDA
The US FDA granted Wockhardt’s new antibiotic, WCK 6777, Fast Track designation for the treatment of complicated urinary tract infections and intra-abdominal infections. It successfully completed Phas...
Wockhardt founder Dr. Habil Khorakiwala honored with lifetime achievement award
Dr. Habil Khorakiwala, the founder and chairman of Wockhardt, has been awarded the Lifetime Achievement Award at the 10th Integrated Health & Wellbeing (IHW) Summit held in Dubai. This prestigious awa...
Wockhardt’s Zaynich™ treats drug-resistant meningitis in clinical case
Wockhardt Limited has announced a significant breakthrough with its investigational drug Zaynich™ (Zidebactam/Cefepime), which has successfully cured a complex case of meningitis caused by a pan-drug ...
Wockhardt refutes Cong allegations of 'rent payments' to Sebi chief
Wockhardt has firmly denied allegations of improper rent payments involving Carol Info Services and disputed claims linking it to certain SEBI orders. Congress media head Pawan Khera raised concerns a...
Buch received rental income from entity under Sebi probe, says Congress
The Public Accounts Committee may summon Sebi chairperson Madhabi Puri Buch following Congress's allegations of conflict of interest. They claim she earned over Rs 2 crore in rental income from a comp...
'What is he afraid of?': Congress on PM Modi's 'inaction' over allegations against Sebi chief
Congress has leveled corruption allegations against Sebi chief Madhabi Puri-Buch, claiming she rented her property to a company regularly dealing with Sebi. Congress leader Pawan Khera pointed out tha...